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An Ashkenazi Jewish Israeli family with two children
affected with severe xeroderma pigmentosum was
investigated. A son, XP12TA, developed skin cancer
at 2 y and died at 10 y. A daughter, XP25TA, now 24 y
old, was sun protected and began developing skin can-
cers at 10 y. Their cultured skin ®broblasts showed
reductions in post-ultraviolet survival (11% of
normal), unscheduled DNA synthesis (10% of
normal), global genome DNA repair (15% of normal),
and plasmid host cell reactivation (5% of normal).
Transcription-coupled DNA repair was normal, how-
ever. Northern blot analysis revealed greatly reduced
xeroderma pigmentosum complementation group C
mRNA. A plasmid host cell reactivation assay assigned
the cells to xeroderma pigmentosum complementa-
tion group C. Cells from both parents and an unaf-
fected child exhibited normal post-ultraviolet-C
survival and normal DNA repair. Sequencing the
xeroderma pigmentosum complementation group C
cDNA of XP12TA and XP25TA revealed a homo-
zygous deletion of two bases (del AT 669±670) in exon
5 with a new termination site 10 codons downstream
that is expected to encode a truncated xeroderma pig-
mentosum complementation group C protein.
Sequence analysis of the xeroderma pigmentosum
complementation group C cDNA in cells from the
parents found identical heterozygous mutations: one
allele carries both the exon 5 frameshift and an exon 15
polymorphism and the other allele carries neither
alteration. Cells from the unaffected brother had two
normal xeroderma pigmentosum complementation
group C alleles. This frameshift mutation in the xero-
derma pigmentosum complementation group C gene
led to reduced DNA repair with multiple skin cancers
and early death. Sun protection delayed the onset of
skin cancer and prolonged life in a sibling with the
same mutation. Key words: cancer genetics/DNA poly-
morphism/DNA repair/skin cancer/sun protection. J Invest
Dermatol 115:974±980, 2000
X
eroderma pigmentosum (XP) is a rare autosomal
recessive disease associated with extreme sensitivity
to sunlight, increased freckling, and a high in-
cidence of neoplasms in sun-exposed parts of the
body in association with defective DNA repair
(Kraemer and Slor, 1985; Bootsma et al, 1998; Kraemer, 1999a, b).
Some XP patients may develop neurologic abnormalities (Kraemer
et al, 1987). XP has been identi®ed in all races throughout the
world (Kraemer et al, 1987) and is more common in the middle
East and Japan than in Europe and the U.S.A.
Genetic complementation identi®ed seven XP complementation
groups (XPA-G) with de®cient DNA nucleotide excision repair
(Bootsma et al, 1998). XP complementation group C (XPC) is the
most prevalent form among North Americans and Europeans
(Bootsma et al, 1998; Kraemer, 1999b) but has not been reported in
Israel. In normal cells DNA repair occurs preferentially in actively
transcribed genes (transcription-coupled repair, TCR) and subse-
quently in the remainder of the genome (global genome repair,
GGR) (Bootsma et al, 1998). XP cells in all complementation
groups have defective GGR. XPC cells uniquely have defective
GGR but normal TCR.
XPC patients exhibit elevated frequency of skin cancers but
rarely have neurologic abnormalities. The molecular defects
responsible for the XPC clinical phenotype were analyzed in only
18 XPC patients (Legerski and Peterson, 1992; Li et al, 1993; Khan
et al, 1998; Cleaver et al, 1999; Chavanne et al, 2000), and none was
from Israel. Here we report the identi®cation of a homozygous AT
deletion in exon 5 of the XPC gene in two Israeli siblings with
severe XP. The resulting frameshift created a new stop codon 10
codons downstream from the mutation.
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MATERIALS AND METHODS
Cell lines and culture conditions Fibroblast cell cultures were
established from skin biopsies of two XP patients (XP12TA, XP25TA),
their parents (XPH26TA, XPH27TA), and a healthy brother (35TA)
(Fig 1). XP1TA and XP3TA skin ®broblasts were established from XP
patients of complementation group D and XP1BE was established from an
XPC patient (Robbins et al, 1974). CS1TA skin ®broblasts are from a
patient with Cockayne syndrome (CS). HSTA and 96TA skin ®broblasts
were obtained from unaffected healthy donors. Normal control ®broblast
culture C5RO was a generous gift from Dr. J. Hoeijmakers, Erasmus
University, Rotterdam, The Netherlands. Normal control cells CRL1876
were obtained from the American Type Culture Collection, Rockville,
MD. Cultures were grown in Dulbecco's modi®ed Eagle's medium
(DMEM) supplemented with 40 mM L-glutamine and with 15% fetal
bovine serum (FBS) (Beit Haemek, Israel). In some experiments antibiotics
were added (penicillin, streptomycin, mycostatin mix; Beit Haemek) and
used according to the manufacturer's recommendations. For unscheduled
DNA synthesis (UDS) measurements cells were cultured in MEMa/
FBS20. Incubations of cell cultures were in a 37°C humidi®ed 5% CO2
incubator. All Israeli patients and donors signed a consent form approved by
the Tel Aviv University Medical School.
Post-ultraviolet-C (UVC) cell survival Cell survival was assessed by
measuring the colony-forming ability of UVC-irradiated cells (germicidal
Philips UVC lamp, predominantly 254 nm). Brie¯y, cells were obtained
from a culture 24 h after splitting and 250 cells were seeded per 60 mm plate
in triplicate using F10 medium supplemented with 40 mM L-glutamine and
20% FBS (Beit Haemek). After 24 h medium was removed and cells were
rinsed once with phosphate-buffered saline (PBS) pH 7 and UV irradiated
at doses of 0±8 J per m2. Complete F10 medium was added and cells were
incubated for 7±10 d until colonies could be observed microscopically.
Medium was removed and the colonies were stained for 30 min with 0.2%
crystal violet in 50% ethanol, rinsed in water, air dried, and counted.
UDS UDS was performed as described previously (Kraemer et al, 1975)
with the following modi®cations. Cells were inoculated into two-well glass
tissue culture chamber slides (Nunc) (100,000 cells per well in 2 ml
MEMa/FBS20 with penicillin and streptomycin), and were re-fed with
MEMa/FBS1 the next day. Six days after inoculation one chamber per
slide was treated with 10 J per m2 UVC after rinsing and re®lling wells with
PBS. Radiolabeling was with methyl 3H-thymidine (Amersham), 10 mCi
per ml MEMa/FBS1, for 2 h, followed by chamber wall and gasket
removal from slide, ®xation, autoradiography with 50% NTB-2 emulsion
(»2 d), developing, and staining with nuclear fast red. Grain counting was
performed within an approximately 6 3 6 mm area in the center of the
wells, using three slides (three irradiated and three unirradiated chambers)
per culture, with about 35 apparently non-S-phase nuclei per chamber.
Nuclei with grain counts greater than two standard deviations above the
mean were discarded as presumed unrecognized S-phase nuclei, after which
the mean was recomputed and used to determine grains per nucleus.
DNA excision repair replication DNA excision repair was
determined using pulse-chase 3H-BrUdR labeling post UVC exposure
and analyzing the isolated DNA in the heavy-light peak after
ultracentrifugation in CsCl as described previously (Slor and Cleaver,
1978). Brie¯y, ®broblast cells in culture dishes (DMEM/15%FBS) were
incubated for 24 h with 0.1 mCi per ml 14C-thymidine (Nuclear Center,
Negev, Israel) to prelabel cellular DNA. Medium was replaced with
DMEM/15%FBS containing 10±6 M FUdR and 1 mM BrUdR (unlabeled).
After 60 min the medium was removed, cells were UVC irradiated (or
sham treated in control cultures), and medium with 3H-BrUdR in place of
thymidine was added. Cells were pulsed for 60 min in radioactive medium
to allow DNA repair. Cellular thymidine synthesis is effectively inhibited
by the presence of the FUdR. The medium was then replaced with
nonradioactive medium (chase) for a further 60 min incubation. DNA was
extracted and ultracentrifuged for 36 h. About 30 fractions were collected
from the bottom of the tube and aliquots were precipitated with 7% cold
trichloroacetic acid, ®ltered through GF/C ®lters, and counted for
radioactivity. The ratio of the 3H/14C in the heavy/light peak
(representing DNA from cells not in S-phase) was used as a measure of
DNA repair.
TCR This assay measures the resumption of RNA synthesis in damaged
cells as a result of DNA repair associated with transcription activity. The
method is slightly modi®ed from the original procedure described by
Mayne and Lehmann (1982). Brie¯y, cells were incubated for 48 h in the
presence of 0.01 mCi per ml 14C-thymidine (Nuclear Center, Israel) to
prelabel cellular DNA. Duplicate or triplicate UV-irradiated (12 J per m2)
or control unirradiated cell-culture plates were pulse-labeled for 60 min
with 3H-uridine (5 mCi per ml; Amersham) either immediately after UV
irradiation or after 24 h of incubation, to measure RNA synthesis before
and after DNA repair. DNA and RNA were precipitated in ice-cold
trichloroacetic acid and collected on nitrocellulose membrane ®lters
(Millipore); radioactivity of the 14C DNA and 3H RNA was determined
by scintillation counting. All RNA synthesis data were normalized to DNA
concentration using the ratio of 3H/14C. RNA synthesis in cells prior to
UV damage was taken as 100%. RNA synthesis immediately after UV
damage was used as the initial inhibition. RNA synthesis 24 h post UV
irradiation represented the ``recovery of RNA synthesis'' from the initial
inhibited level immediately after damage, expressing DNA repair in
actively transcribed genes. Recovery of RNA synthesis is calculated from
the ratio of RNA synthesis in UV-irradiated cells to RNA synthesis in
unirradiated cells.
Northern blotting Total cytoplasmic RNA was isolated from cells,
separated by electrophoresis, and transferred to a positively charged nylon
membrane. Northern blot hybridization was performed as described
previously (Khan et al, 1998) using a 32P-labeled XPC cDNA fragment
3.5 kb in size. Autoradiographic band intensities were measured with a laser
densitometer (Molecular Dynamics, Sunnyvale, CA). After stripping off the
XPC probe the same membrane was re-probed with b-actin cDNA as an
internal standard.
Host cell reactivation and complementation group assignment The
pCMVLuc reporter gene plasmid (a generous gift from M. Hedayati and L.
Grossman, Johns Hopkins University, Baltimore, MD) was used to measure
post-UV host cell reactivation. In this construct the original SV40
promoter of the luciferase gene containing plasmid pGL3 (Promega) was
replaced with a CMV promoter. Host cell reactivation (Protic-Sabljic and
Kraemer, 1985) was performed as described previously (Emmert et al,
2000). Brie¯y, 25 ml of CsCl-puri®ed pCMVLuc either UV irradiated
(1000 J per m2) or unirradiated was transfected into 0.15 3 106 cells seeded
onto 35 mm culture dishes using 3 ml lipofectamine (BRL Gibco) in a total
volume of 1 ml for 5 h. After 48 h luciferase activity was measured with a
luminometer (Monolight 2010, Analytical Luminescence Laboratory, San
Diego, CA) using Luciferase Assay Reagent (Promega) as recommended by
the manufacturer. Total protein in the cell lysates was measured by Bio-rad
Protein Assay. Relative luciferase activities are presented as percentage of
activities obtained with UV-irradiated plasmids versus unirradiated control
plasmids. In order to assign the XP12TA and XP25TA cells to a speci®c
complementation group (Khan et al, 1998) simultaneous cotransfection was
performed with 0.25 mg of an XPC cDNA containing plasmid (Legerski
and Peterson, 1992), or an XPD cDNA containing plasmid (Carreau et al,
1995), or with pEBS7 (vector without the XPC gene; Legerski and
Peterson, 1992) along with UV-irradiated or unirradiated pCMVLuc
plasmid.
Figure 1. Pedigree of Israeli XPC family. The affected proband
XP12TA (arrow) and his affected sister XP25TA have a homozygous
mutation (del AT 669±70) in exon 5 of the XPC gene. Both parents
XPH26TA and XPH27TA are clinically normal and are heterozygous for
the same mutation. The clinically normal brother 35TA does not have this
XPC mutation. The parental allele with the XPC mutation also carries a
polymorphic marker in exon 15 2920C whereas the normal allele is 2920A.
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RNA/DNA extraction, DNA ampli®cation, and nucleotide
sequence analysis RNA and DNA were isolated utilizing TRIzol and
DNAzol reagents as per the vendor's protocol (Gibco BRL). The ®rst
strand cDNA was synthesized utilizing 2 mg total RNA as described
previously (Khan et al, 1998) and was used to amplify the entire coding
region of the XPC gene by nested polymerase chain reaction (PCR) (Li
et al, 1993). Sequencing was performed by cycle sequencing employing
dideoxy termination chemistry and an ABI 373 A Automated DNA
sequencer (PE Applied Biosystems). To analyze the linkage between the
exon 5 and exon 15 genetic changes, the 3.5 kb XPC cDNA was ampli®ed,
subcloned into the pCR2.1±TOPO vector (TOPO cloning kit,
Invitrogen), and used in DNA sequence analysis. The mutation
identi®ed in the XPC cDNA was also con®rmed by direct sequencing of
the PCR ampli®ed genomic DNA region harboring these changes.
RESULTS
Case report and pedigree Figure 1 describes the pedigree of
the investigated family [family C in Kraemer and Slor (1985)]. Both
parents were clinically normal. They are descendants of Polish
Ashkenazi Jewish families without known consanguinity. The
family lives on a farm in Israel in a sunny area without natural
shade. The family had a healthy son, 35TA, born 1971, and two
affected children, a son XP12TA (the proband), born 1974, and a
daughter XP25TA, born 1976. XP12TA when exposed to sunlight
did not develop severe sunburn with blisters. Instead by 3 mo of age
he developed markedly increased freckling on sun-exposed skin,
which was later followed by actinic keratoses. His ®rst skin cancers
were basal cell carcinomas on his lip and cheek at 2 y of age.
Growth and development were normal and he had no neurologic
abnormalities (Fig 2, left). He died in 1984 at 10 y of age having
more than 20 cutaneous neoplasms including four squamous cell
carcinomas, two lentigo-melanomas, and multiple basal cell
carcinomas involving his face, neck, and eyes. The cause of death
is not known. An autopsy was not performed. The affected sister
XP25TA was protected from sun exposure early in life. Her
outdoor activities were limited to times when the sun was down.
When going outdoors during daylight hours she used sun-
protective clothing and topical sunscreens. By 1 y of age she had
freckling of her face and neck. Her growth and development were
normal and she had no neurologic abnormalities (Fig 2, right). She
developed her ®rst skin cancer at age 10 y. By age 24 y she had 10
skin neoplasms on her face, head, and neck: ®ve basal cell
carcinomas, two squamous cell carcinomas, one melanoma in situ,
one super®cial spreading melanoma, and, in 1995, an ulcerated
melanoma 4.5 mm thick on her forehead.
Reduced post-UVC cell survival Cell survival was assessed by
measuring post-UVC colony-forming ability of ®broblast cells
obtained from XP12TA and XP25TA (affected siblings), from
XPH27TA (father), from 35TA (healthy brother), and from two
normal healthy donors (96TA and HSTA) (Fig 3A). Parental cells
and cells from the healthy brother and from the two healthy
controls exhibited similar survival patterns with about 75% survival
at a dose of 8 J per m2. In marked contrast, the XP cells had about
2% survival at the same UV dose. The D37 (dose that results in 37%
survival) was calculated to be 14 J per m2 for the normal cells and
1.6 J per m2 for the XP12TA and XP25TA cells, indicating that the
D37 was 11% of normal.
Reduced UDS DNA repair measured by autoradiography
showed 10% of normal post-UV UDS in XP12TA and XP25TA
cells in comparison to the normal control cells C5RO and
CRL1876. The XPC cell line XP1BE had 14.4% of normal post-
UV UDS in the same experiment.
Reduced repair replication Post-UV nucleotide excision
GGR was measured with the BrUdR-CsCl repair replication
method utilizing a CsCl gradient (Fig 3B). A heavy-light peak
(representing non-S-phase DNA) was identi®ed from the ratio of
3H-labeled BrUdR to prelabeled cellular 14C DNA. XP12TA and
XP25TA showed excision repair levels of 12% and 13% compared
to normal control (96TA) cells. Cells of both parents (XPH27TA
and XPH26TA) exhibited DNA excision repair levels similar to the
normal control 96TA cells. Cells obtained from a severe XPD
patient (XP1TA) had about 8% of normal DNA repair.
Normal TCR TCR was measured as recovery of RNA
synthesis in cells 24 h after exposure to UVC irradiation
(Fig 3C). Fibroblasts of all members of this XP family as well as
®broblasts from the normal control (96TA), from two severe XPD
cases (XP1TA and XP3TA), and from a patient with CS (CS1TA)
were studied. CS cells are defective in TCR but exhibit normal
GGR (Bootsma et al, 1998). XPC cells uniquely have normal TCR
and defective GGR, whereas XPA and XPD cells have defective
TCR and GGR (Bootsma et al, 1998). The CS cells exhibited 35%
TCR, characteristic of other CS cells, and, as expected, the XPD
cells exhibited less than 5% TCR (Fig 3C). Cells from both parents
and their normal son and cells of both XP siblings exhibited TCR
in the normal range. The combination of reduced UDS with
normal TCR strongly suggested that XP12TA and XP25TA
belong to complementation group C.
Reduced XPC mRNA The level of XPC mRNA in cells of
most, if not all, XPC patients is markedly reduced (Legerski and
Peterson, 1992; Khan et al, 1998; Chavanne et al, 2000). We have
measured the level of XPC mRNA in one of the affected siblings
(XP25TA) and in normal cells using northern blot analysis. There
was a greatly reduced level of the XPC mRNA in XP25TA cells
compared to XPC mRNA in normal cells (Fig 4, inset). Levels of
actin mRNA, used as an internal control, were similar in both cell
types.
Assignment of XP cells to complementation group C Host
cell reactivation of UV-irradiated luciferase reporter gene plasmid
was greatly reduced in transfected XP12TA ®broblasts compared to
normal cells, indicating the reduced DNA repair capacity for DNA
photoproducts in these cells (Fig 4). Fibroblasts from both parents
exhibited post-UV host cell reactivation similar to that of normal
control cells (data not shown). Cotransfection of the UV-irradiated
luciferase plasmid with plasmids carrying cloned XPC, XPD, or no
Figure 2. Israeli XP siblings. (Left) The affected proband, XP12TA, at
8 y of age. He was of Polish Jewish ancestry and had severe clinical XP with
his ®rst skin neoplasm by 2 y of age. He has marked freckling, actinic
keratoses, and multiple skin cancers on sun-exposed portions of his face,
arms, and neck. A skin neoplasm on his right temple was grafted with skin
from a sun-shielded site resulting in a region of less pigmentation. (Right)
The affected sister, XP25TA, at 3 y of age. She has minimal freckling on
her face. She has been sun protected since birth.
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cDNA was performed. Only cotransfection with a plasmid
containing the XPC cDNA led to a markedly increased post-UV
host cell reactivation in the XPTA12 cells (Fig 4), thus assigning
the XP12TA proband to the XPC complementation group.
DNA sequence analysis of the XPC gene Sequencing was
performed on the entire 3.5 kb XPC cDNA and on selected
portions of XPC genomic DNA from both patients, their parents,
and the normal brother (Fig 5). Sequencing of the exon 5 region of
genomic DNA from the clinically normal son (35TA) showed the
normal DNA sequence (Fig 5, top). cDNA from the affected
siblings XP12TA (Fig 5, middle) and XP25TA (data not shown)
showed a homozygous deletion of two bases (AT) in exon 5 of the
XPC gene at nucleotide location 669±670. We subcloned the
entire 3.5 kb XPC cDNA from XP12TA. All subclones contained
the del AT 669±670, supporting the observation that it was
homozygous. This frameshift mutation created a new termination
signal (TAA) 10 codons downstream (Fig 5, middle). Such a
mutation would be expected to encode a truncated, nonfunctional
197 amino acid long XPC protein rather than the full length 940
Figure 3. UV sensitivity of XP12TA and XP25TA cells. (A) Reduced
post-UV cell survival of XP12TA and XP25TA ®broblasts. Colony-
forming ability of XP12TA and XP25TA ®broblasts following exposure to
various doses of UVC was reduced compared to that of the normal control
®broblasts (96TA and HSTA). Fibroblasts from the father (XPH27TA) and
the unaffected brother (35TA) had normal post-UV colony-forming
ability. Each point represents the mean 6 SEM of triplicate samples. (B)
Reduced nucleotide excision repair of XP12TA and XP25TA following
UVC. Repair replication following exposure to 12 J per m2 UVC was
measured using 3H-BrUdR labeled ®broblasts and analyzed by CsCl
ultracentrifugation (details in Materials and Methods). The mean 6 SEM of
triplicate samples is presented. There was a similar reduction in nucleotide
excision repair in the ®broblasts from both affected siblings (XP12TA and
XP25TA). XP1TA (XPD) had reduced nucleotide excision repair in
comparison to the normal cells (96TA). Fibroblasts from both parents
(XPH27TA and XPH26TA) had normal excision repair. (C) Normal TCR
of XP12TA and XP25TA following exposure to UVC. Fibroblasts were
exposed to 12 J per m2 UVC and incorporation of 3H-UdR into RNA was
measured immediately and then 24 h later. The recovery of RNA synthesis
in triplicate samples (6 SEM) is shown. CS1TA had intermediate reduction
in TCR between the XPD cells (XP1TA and XP3TA) and the normal cells
(96TA). The XP12TA and XP25TA cells both had nearly normal TCR.
Figure 4. XPC mRNA and complementation group assignment.
Inset: Reduced XPC mRNA in XP25TA cells. RNA was extracted from
XP25TA and normal cells, separated by electrophoresis, transferred to a
membrane, and probed for XPC mRNA and then for b-actin mRNA. The
level of XPC mRNA was markedly reduced in XP25TA cells compared to
the normal cells. Reduced post-UV host cell reactivation and assignment of
XP12TA cells to XPC complementation group by host cell reactivation.
XP12TA cells (solid bars) were transfected with 1000 J per m2 UVC-treated
plasmid pLUC along with another plasmid carrying the wild type XPD
cDNA (pXPD), the wild type XPC cDNA (pXPC), or no cDNA (pEBS7).
Normal cells (96TA) (hatched bar) were also transfected with 1000 J per m2
UVC-treated pLUC. The data represent the mean 6 SEM of triplicate
samples. The XP12TA cells showed reduced plasmid host cell reactivation
that was only corrected by cotransfection with the XPC cDNA containing
plasmid (*) indicating that these cells are in complementation group C.
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amino acid wild type XPC protein. Sequencing genomic DNA
from the parents (XPH26TA, Fig 5, bottom; and XPH27TA, data
not shown) indicated that both parents are heterozygous for this AT
deletion in exon 5 of the XPC gene. Comparing this sequence
(Fig 5, bottom) with that of the normal child (Fig 5, top) and with
that of the affected child (Fig 5, middle) shows double sequences
after the frameshift as one chromosome has the normal sequence
and the other has a loss of two bases. Genomic DNA from
XP12TA did not show this double sequence, further indicating that
the deletion mutation was homozygous.
An additional transversion mutation of A to C at nucleotide 2920
was identi®ed in exon 15. This missense mutation results in a
change of amino acid 939 from lysine to glutamine. We have found
that this change is a common polymorphism that retains the
functional ability of the XPC cDNA to correct the defect in post-
UV host cell reactivation (Khan et al, 2000). Subcloning of the
entire 3.5 kb XPC cDNA indicates that this A2920C mutation is
on the same allele that carries the AT deletion in both parents and
in the affected siblings (Fig 1). The parents have one allele that
carries both the exon 5 frameshift and the exon 15 polymorphism
and another allele that has neither mutation. The affected patients
are homozygous for both mutations. The unaffected brother
inherited the two normal alleles from his parents.
DISCUSSION
XP clinical features and complementation groups Patients
with XP are sun sensitive with early onset of freckling and skin
cancer in parts of the body exposed to UV radiation (Kraemer et al,
1987, 1994; Bootsma et al, 1998; Kraemer, 1999b). The patients
with classical XP have symptoms con®ned to sun-exposed parts of
the body (skin, anterior eyes, lips, tip of the tongue). Protection
from sunlight results in prevention of many of these serious
abnormalities (Fig 2). Some XP patients, in addition, have
neurologic abnormalities consisting of progressive loss of
coordination, intellectual functioning, and hearing. The XP
phenotype can result from a mutation in one of the seven XP
genes (A-G) involved in DNA nucleotide excision repair (Bootsma
et al, 1998), or in the XPV gene that codes for DNA polymerase h
that can replicate through a damage-containing DNA template
(Johnson et al, 1999; Masutani et al, 1999).
Characterization of the various mutations in XP and the resulting
clinical phenotypes is essential for an understanding of the
relationship between the genotype and the phenotype. Most
patients with classical XP are in XP complementation groups C, E,
or F but they can also be found in complementation groups A, D,
and G. XP patients with neurologic abnormalities are usually in
complementation groups A, B, D, or G but they can also be found
in complementation group C. Thus, there is marked clinical
heterogeneity in different complementation groups. Clinical
heterogeneity is also found within the same complementation
group. For example, a mutation in the XPD gene may cause one of
four different clinical syndromes: XP without neurologic disease,
XP with neurologic disease, trichothiodystrophy (a disorder with
sulfur-de®cient brittle hair, sun sensitivity, ichthyosis, and neuro-
logic degeneration without cancer), or a combination of XP with
CS ± the XP/CS complex (Bootsma et al, 1998).
The XP genes are localized on different chromosomes, and the
relatively few mutations identi®ed in these genes were recently
summarized (Cleaver et al, 1999). Only 20 mutations in 18 XP
patients have been reported in the XPC gene (Li et al, 1993; Khan
et al, 1998; Cleaver et al, 1999; Chavanne et al, 2000) and none was
from Israel. In this investigation we have studied the genotype per
phenotype relationship in two XP siblings of an Ashkenazi Jewish
family.
XP in different populations XP is a very rare disease (estimated
frequency 1 in 100,000 to 1 in 1,000,000); however, XP patients
have been identi®ed throughout the world in all races (Kraemer
et al, 1987). There appears to be a higher frequency in Japan, North
Africa, and parts of the Middle East. In 1985 we described 11 XP
kindreds in Israel (Kraemer and Slor, 1985). Subsequently an
additional 11 families have been identi®ed. Of these 22 families,
only one was Ashkenazi Jewish [family C in Kraemer and Slor
(1985)].
XPC and DNA repair assays Defective nucleotide excision
repair leads to increased sensitivity of cells to killing by UV
radiation (Fig 3A). Cells from patients in XPC have moderately
increased post-UV hypersensitivity that is usually intermediate
between that of XPA cells and normal cells. Heterozygotes who are
carriers of XP mutations have normal post-UV cell killing.
Nucleotide excision repair can be measured by several different
assays. Autoradiographic measurement of DNA repair by post-UV
UDS assesses repair at the single-cell level in cells that are not in the
S-phase of the cell cycle. As in our patients, UDS is typically in the
range of 10%±20% of normal in XPC cells (Kraemer et al, 1975;
Bootsma et al, 1998).
Repair replication, another DNA repair assay, involves growing
cells in medium containing BrUdR, which is incorporated into
cells in place of thymidine. BrUdR is heavier than thymidine and
doubly labeled replicated strands of DNA containing BrUdR can
be separated from singly labeled and unlabeled DNA by use of a
CsCl gradient. Incorporation of 3HTdR into singly labeled DNA
after UV treatment re¯ects DNA repair. As most of the DNA
analyzed in this assay is considered bulk, nontranscribing DNA, the
assay primarily measures GGR. XP cells in complementation
groups A-G are defective in GGR. XPC cells typically have
reduced repair replication in the range of 10%±20% of normal
(Fig 3B).
Figure 5. DNA sequence of Israeli family showing frameshift
mutation in XPC exon 5. The sequence of a portion of the genomic
DNA of XPC exon 5 from the normal sibling (35TA, upper), the affected
XP patient (XP12TA, middle), and their mother (XPH26TA, lower) was
determined by use of an ABI automated sequencer. The normal DNA and
amino acid sequence beginning at base pair 668 is indicated by a broad
horizontal line. The two-base deletion of AT at bp 669±70 (D) that results
in a change of the amino acid sequence and a new stop codon (*) is
indicated by a narrow horizontal line. 35TA has the homozygous normal
sequence, XP12TA has a homozygous frameshift mutation, and XPH26TA
is heterozygous for both sequences. (Note the single sequence signals in
35TA and XP12TA and double sequence signals in XPH26TA after bp
668.)
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DNA damage to transcribed genes is preferentially repaired in
normal cells (Bootsma et al, 1998). XP cells in all complementation
groups except XPC have defective TCR. XPC cells have normal
TCR but reduced GGR. Conversely, cells from patients with CS
have normal GGR and reduced TCR. We measured TCR as the
recovery of RNA synthesis 24 h after exposure to UV. We found
the greatest reduction in TCR in XPD cells, and an intermediate
reduction in CS cells (Fig 3C). The normal TCR in the cells from
the XP patients (Fig 3C) in combination with reduced UDS (10%
of normal) and reduced GGR (Fig 3B) is characteristic of XPC
cells.
Low levels of mRNA are often associated with mutations that
result in production of truncated proteins. This process has been
called ``nonsense mediated message decay'' (Nagy and Maquat,
1998). Cells from the few XPC patients studied have low mRNA
levels (Li et al, 1993; Khan et al, 1998; Chavanne et al, 2000) and
most have truncated XPC protein. The Israeli XP patient XP25TA
also has low XPC mRNA (Fig 4).
The ability of cells to repair DNA damage in transfected plasmids
is called ``host cell reactivation''. This is an extremely sensitive assay
that can detect repair of a single photoproduct in the coding
sequence of the transfected gene (Protic-Sabljic and Kraemer,
1985). Reduced post-UV plasmid host cell reactivation is seen in all
nucleotide excision repair defective XP cells. We found reduced
post-UV plasmid host cell reactivation in XP12TA cells (Fig 4).
Cloning of the XP genes allowed development of a rapid
complementation assay for DNA repair de®cient human syn-
dromes. Plasmids containing the cloned cDNA are cotransfected
into host cells simultaneously with UV-damaged reporter plasmid
(Carreau et al, 1995; Khan et al, 1998). The plasmid that corrects
the DNA repair defect, as expressed in increased host cell
reactivation, carries the XP gene that is defective in the host cells.
Using this assay we were able to assign XP12TA to XP
complementation group C (Fig 4).
Function of XPC protein The XP genes are involved in DNA
nucleotide excision repair. The encoded proteins work in concert.
They have functions such as DNA damage recognition (XPC,
XPE, and XPA), unwinding the DNA by helicase activities (XPB
and XPD), incisions on both sides of the lesion (XPF and XPG),
re-synthesis by DNA polymerase, which uses the opposite intact
strand as template, and ligation of the newly synthesized DNA to
the parental DNA by DNA ligase (Lindahl and Wood, 1999).
Except for XPC all other XP gene products are associated with
both GGR and TCR. The XPC gene product is not involved in
TCR but rather uniquely involved only in GGR and in DNA
repair of the nontranscribed strands in active genes.
The XPC gene is located on chromosome 3p25.1 and encodes a
940 amino acid single stranded DNA binding protein (Bootsma
et al, 1998). The XPC protein is tightly associated in vivo with
another protein, HHR23B, which is encoded by a gene closely
linked to the XPC gene (Masutani et al, 1994). The XPC-
HHR23B complex acts in the initial step of damage recognition in
GGR (Sugasawa et al, 1998), but is then released from the
preincision complex before strand incision occurs (Wakasugi and
Sancar, 1998). There is evidence that the XPC gene product is
involved in selective repair of one type of UV photoproduct (the
cyclobutane pyrimidine dimer rather than the 6±4 photoproduct)
(Emmert et al, 2000). Transient nucleosome unfolding occurs
during nucleotide excision repair, and this unfolding may require
the XPC protein (Baxter and Smerdon, 1998). The XPA protein
also binds to DNA damage sites following the binding by XPC-
HHR23B complex where it acts as a damage veri®cation factor
(Sugasawa et al, 1998). As the XPC protein is not involved in
TCR, it is assumed that its function is performed by a stalled RNA
polymerase.
XPC mutations The biologic consequences of mutations in the
XPC gene are responsible for the clinical phenotypes associated
with this gene. Identi®cation of the mutation site and type in an
XPC patient is important in order to understand the correlation
between a mutation and the cellular and clinical phenotypes. A
mutation may alter the active site of the XPC protein, impairing its
ability to bind preferentially to DNA damage sites, or its ability to
bind with its associated protein HHR23B, or its ability to interact
with other DNA repair factors. A mutation may create a deletion,
an insertion, or an alternative splice site, which cause a frameshift
that results in a premature termination codon, thus resulting in an
incomplete and often short-lived mRNA and a nonsense truncated
protein.
Mutations in the XPC gene have been reported in 18 other
patients (Li et al, 1993; Khan et al, 1998; Cleaver et al, 1999;
Chavanne et al, 2000). Most of these have been frameshift or splice
mutations that lead to premature termination of the XPC message
leading to a truncated protein. In this kindred XP12TA had a
deletion of two bases in exon 5 leading to a premature termination
10 codons downstream. The other mutation was an A to C
transversion in exon 15 leading to a change of the next to the last
amino acid from lysine to glutamine. This change was present in
both parents on the same allele as the deletion mutation (Fig 1).
We have determined that this change still retains normal XPC
function in an in vivo DNA repair assay (Khan et al, 2000). Further,
this change was commonly seen in the XPC gene of normal
individuals. Thus it is a normal polymorphism (Chavanne et al,
2000).
This family emigrated from Poland where they had lived for
many generations. The family reported no known consanguinity.
Both parents carry an allele with an AT deletion in exon 5 (del AT
669±670), however, and a functional polymorphic transversion
mutation in exon 15 (A2920C) (Fig 1). The fact that the DNA
alterations in exons 5 and 15 are identical in both parents and
located on the same allele strongly suggests that they originated in a
common ancestor. The healthy child has two normal XPC alleles.
CONCLUSION
This newly described frameshift mutation in the XPC gene led to
reduced DNA repair with severe clinical disease, multiple skin
cancers beginning at age 2 y, and death by age 10 y in one sibling.
Sun protection delayed the onset of skin cancer to age 10 and
prolonged life to more than 23 y in another sibling with the same
mutation.
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